A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
- Conditions
- Chronic Kidney Disease (CKD)Gout
- Interventions
- Registration Number
- NCT03226899
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Brief Summary
This study evaluates the safety and efficacy of lesinurad administered with an XOI versus a placebo plus an XOI in gout participants who have moderate renal impairment and who are not at target level of serum urate (sUA).
- Detailed Description
This postmarketing study is a randomized, double-blind, placebo-controlled study to evaluate safety (with particular focus on renal and cardiovascular events) and efficacy of lesinurad 200 mg once daily (QD) in combination with an XOI for up to 24 months compared with XOI monotherapy, in participants with gout and moderate renal impairment who have not reached target sUA levels (\<6.0 mg/dL) on an XOI alone.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 242
- Subject is able to understand the study procedures, the risks involved, and willing to provide written informed consent before the first study related activity.
- Subject is willing to adhere to the protocol schedule.
- Subject is ≥ 18 years and ≤ 85 years of age.
- Subject has a diagnosis of gout.
- Subject has moderate renal impairment with estimated creatinine clearance (eCrCl; calculated by the Cockcroft-Gault formula using ideal body weight) 25.0 to ≤ 65.0 mL/min at Screening Visits 1 and 2 and an average eCrCl for both screening visits of 30.0 to < 60.0 mL/min.
- Subject has been taking an XOI as ULT indicated for the treatment of gout for at least 4 weeks prior to Screening at a stable, medically appropriate dose, as determined by the Investigator. The minimum dose of allopurinol is 200 mg daily, and the minimum dose of febuxostat is the lowest approved dose per the local product label.
- Subject has a serum uric acid level ≥ 6.0 mg/dL (357 µmol/L) at Screening Visits 1 and 2.
- Subject is male or female; females must not be pregnant or breastfeeding and females of childbearing potential must agree to use nonhormonal contraception during the Screening Period and while taking investigation product (IP).
- Subject has a body mass index < 45 kg/m^2.
- Subject had unstable angina, New York Heart Association class III or IV heart failure, myocardial infarction, or stroke within the last 6 months prior to randomization; or had a deep venous thrombosis within the previous 3 months prior to randomization.
- Subject has uncontrolled hypertension (defined as systolic pressure above 160 or diastolic pressure above 95 mm Hg at either Screening Visits 1 or 2).
- Subject has severe hepatic impairment (defined as Child-Pugh Class C) or is known human immunodeficiency virus (HIV) positive.
- Subject is a solid organ transplant recipient.
- Subject has a urine protein of 3+ or higher by dipstick by the central laboratory at Screening Visit 2.
- Subject has a history of glomerulonephritis.
- Subject is taking valpromide, progabide, valproic acid, or other known inhibitors of epoxide hydrolase, or subject is taking ranolazine, cyclosporine, azathioprine or mercaptopurine.
- Subject is receiving chronic treatment with more than 325 mg of salicylates per day.
- Subject is unable to initiate gout flare prophylaxis with colchicine or low-dose oral corticosteroids at Baseline.
- Subject is taking any other drug approved for use as a urate-lowering medication other than allopurinol or febuxostat (eg, pegloticase, probenecid, benzbromarone) within 4 weeks prior to Screening or during Screening.
- For subjects who will be taking colchicine for gout flare prophylaxis: Subject is taking, or anticipated to take during the first 6 months on study, moderate or strong Cytochrome P450 3A4 (CYP3A4) inhibitors (ie, verapamil or diltiazem, clarithromycin, and fluconazole; or grapefruit or grapefruit juice).
- Subject previously participated in a clinical study involving lesinurad (RDEA594) or verinurad (RDEA3170) and received active treatment or placebo, or has taken commercially-available lesinurad.
- Subject has a gout flare during the Screening Period.
- Subject is pregnant or breastfeeding.
- Subject consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor).
- Subject has a history of malignancy and has been on active treatment within the previous 5 years prior to randomization with the exception of non-melanoma skin cancer, treated in situ Grade 1 cervical cancer, or treated ductal carcinoma in situ of the breast.
- Subject has been hospitalized (other than for elective surgery) or received intravenous contrast (eg, for computerized tomography (CT) scan or any angiography) within 1 month prior to Screening or during Screening.
- Subject has participated in a clinical trial within 8 weeks prior to Screening.
- Subject has any other medical or psychological condition, which in the opinion of the Investigator might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or to complete the study.
- The maximum number of subjects in the eCrCl stratification subgroup has been reached.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Lesinurad + XOI colchicine lesinurad 200 mg oral tablet QD plus a stable, medically appropriate dose of an XOI Placebo + XOI XOI placebo tablet QD plus a stable, medically appropriate dose of an XOI Lesinurad + XOI Lesinurad lesinurad 200 mg oral tablet QD plus a stable, medically appropriate dose of an XOI Placebo + XOI Placebo placebo tablet QD plus a stable, medically appropriate dose of an XOI Lesinurad + XOI XOI lesinurad 200 mg oral tablet QD plus a stable, medically appropriate dose of an XOI Lesinurad + XOI corticosteroids lesinurad 200 mg oral tablet QD plus a stable, medically appropriate dose of an XOI Placebo + XOI colchicine placebo tablet QD plus a stable, medically appropriate dose of an XOI Placebo + XOI corticosteroids placebo tablet QD plus a stable, medically appropriate dose of an XOI
- Primary Outcome Measures
Name Time Method Percentage of Participants Who Achieve Serum Urate (sUA) < 6.0 mg/dL at Month 6 Month 6
- Secondary Outcome Measures
Name Time Method Percentage of Participants Who Achieve sUA < 6.0 mg/dL Over Time Baseline, Months 1, 3, 6, 9, 12, 15, 18 Change From Baseline in sUA Over Time, Including the Last Value On and Off Treatment Baseline, Months 1, 3, 6, 9, 12, 15, 18 Percent Change From Baseline in sUA Over Time, Including the Last Value On and Off Treatment Baseline, Months 1, 3, 6, 9, 12, 15, 18 Change From Baseline in Estimated Creatinine Clearance (eCrCl) at Month 24 Baseline, 24 months The eCrCl was calculated by the Cockcroft-Gault formula using ideal body weight.
Percent Change From Baseline in eCrCl at Month 24 Baseline, 24 months The eCrCl was calculated by the Cockcroft-Gault formula using ideal body weight.
Change From Baseline in eCrCl Over the Study Period, Including the Last Value On and Off Treatment Baseline, Months 1, 3, 6, 9, 12, 15, 18 The eCrCl was calculated by the Cockcroft-Gault formula using ideal body weight.
Percent Change From Baseline in eCrCl Over the Study Period, Including the Last Value On and Off Treatment Baseline, Months 1, 3, 6, 9, 12, 15, 18 The eCrCl was calculated by the Cockcroft-Gault formula using ideal body weight.
Percentage of Participants With Serum Creatinine (sCr) Elevations (≥1.5 × Baseline) Over the Study Period up to 18 months Percentage of Participants Meeting Criteria (eg, Based on sCr or eCrCl Criteria) for Treatment Discontinuations Over the Study Period up to 18 months Kidney function was monitored throughout the study by measuring sCr and calculating eCrCl by Cockcroft-Gault formula using ideal body weight. Treatment discontinuations were required if a participant experienced an absolute sCr ≥4.0 mg/dL or an eCrCl \<20 mL/min (based on central laboratory results).
Percentage of Participants Renal-Related and Kidney Stone Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From first dose of study drug through each participant's study duration, up to approximately 18 months. Renal-related and kidney stone events were based on Medical Dictionary for Regulatory Activities (MedDRA) "Renal and Urinary Disorders" system organ classification. AEs that started on or after the first dose of study drug in this study, or those AEs with onset prior to the first dose of study drug but worsened after the first dose of study drug, were considered treatment emergent.
Percentage of Participants With Contributing Factors to Renal SAEs as Adjudicated by the Renal Event Adjudication Committee (REAC) From first dose of study drug through each participant's study duration, up to approximately 18 months. Percentage of Participants With Cardiac Event Adjudication Committee (CEAC)-Adjudicated Major Adverse Cardiovascular Events (MACEs) From first dose of study drug through each participant's study duration, up to approximately 18 months. MACEs are defined as Cardiovascular Death, Nonfatal Myocardial Infarction, and Nonfatal Stroke.
Incidence of CEAC-Adjudicated MACEs or Hospitalization for Unstable Angina (MACE+) From first dose of study drug through each participant's study duration, up to approximately 18 months. MACEs are defined as Cardiovascular Death, Nonfatal Myocardial Infarction, and Nonfatal Stroke.
Trial Locations
- Locations (116)
Central Alabama Research
🇺🇸Birmingham, Alabama, United States
Southern Arizona VA Health Care System
🇺🇸Tucson, Arizona, United States
Medvin Clinical Research
🇺🇸Covina, California, United States
Northern California Research
🇺🇸Sacramento, California, United States
Capital Nephrology Medical Group
🇺🇸Sacramento, California, United States
Inland Rheumatology Clinical Trials, Inc
🇺🇸Upland, California, United States
Medvin Clinical Research - Whittier
🇺🇸Whittier, California, United States
Western Nephrology-Westminster
🇺🇸Westminster, Colorado, United States
New England Research Associates, Llc
🇺🇸Trumbull, Connecticut, United States
Arthritis, Autoimmune, & Allergy LLC
🇺🇸Daytona Beach, Florida, United States
Scroll for more (106 remaining)Central Alabama Research🇺🇸Birmingham, Alabama, United States